150 related articles for article (PubMed ID: 3632919)
21. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes.
Weiner LM; Steplewski Z; Koprowski H; Litwin S; Comis RL
Cancer Res; 1988 Feb; 48(4):1042-6. PubMed ID: 3123051
[TBL] [Abstract][Full Text] [Related]
22. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
23. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy.
Schomburg A; Kirchner H; Lopez-Hänninen E; Menzel T; Rudolph P; Körfer A; Fenner M; Poliwoda H; Atzpodien J
Am J Clin Oncol; 1994 Jun; 17(3):199-209. PubMed ID: 7910716
[TBL] [Abstract][Full Text] [Related]
24. Recombinant interferon-gamma lacks activity against metastatic colorectal cancer but increases serum levels of CA 19-9.
O'Connell MJ; Ritts RA; Moertel CG; Schutt AJ; Sherwin SA
Cancer; 1989 May; 63(10):1998-2004. PubMed ID: 2784711
[TBL] [Abstract][Full Text] [Related]
25. Treatment of patients with disseminated colorectal cancer with recombinant human alpha 2-interferon. Studies on the immune system.
Einhorn S; Wasserman J; Lundell G; Blomgren H; Cedermark B; Jarstrand C; Petrini B; Strander H; Theve T; Ohman U
Int J Cancer; 1984 Feb; 33(2):251-6. PubMed ID: 6229496
[TBL] [Abstract][Full Text] [Related]
26. A phase I trial of recombinant leukocyte alpha 2 interferon in patients with advanced malignancy.
Muss HB; Richards F; Homesley HD; Spurr CL; Rudnick SA; Stuart JJ; Plunkett S; Welander C; Caponera M; White DR
Am J Clin Oncol; 1985 Apr; 8(2):97-107. PubMed ID: 3834792
[TBL] [Abstract][Full Text] [Related]
27. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
28. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
[TBL] [Abstract][Full Text] [Related]
29. Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma.
Kuzmits R; Kokoschka EM; Micksche M; Ludwig H; Flener R
Oncology; 1985; 42 Suppl 1():26-32. PubMed ID: 4080298
[TBL] [Abstract][Full Text] [Related]
30. Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens.
Schomburg A; Kirchner H; Atzpodien J
Acta Haematol; 1993; 89(3):119-31. PubMed ID: 8362600
[TBL] [Abstract][Full Text] [Related]
31. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.
Lai CL; Wu PC; Lok AS; Lin HJ; Ngan H; Lau JY; Chung HT; Ng MM; Yeoh EK; Arnold M
Br J Cancer; 1989 Dec; 60(6):928-33. PubMed ID: 2557881
[TBL] [Abstract][Full Text] [Related]
32. Natural killer response to exogenous interferon in delta hepatitis: boost or depression defined within the first week of therapy.
Actis GC; Maran E; Rosina F; Saracco G; Rocca G; Rizzetto M; Bonino F; Verme G
Digestion; 1987; 37(1):51-8. PubMed ID: 3609505
[TBL] [Abstract][Full Text] [Related]
33. Recombinant interferon alfa given before and in combination with standard chemotherapy in children with acute lymphoblastic leukemia in first marrow relapse: a Pediatric Oncology Group pilot study.
Ochs J; Brecher ML; Mahoney D; Vega R; Pollock BH; Buchanan GR; Whitehead VM; Ravindranath Y; Freeman AI
J Clin Oncol; 1991 May; 9(5):777-82. PubMed ID: 2016619
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of recombinant leukocyte A interferon in advanced malignant melanoma.
Elsässer-Beile U; Drees N; Neumann HA; Schöpf E
J Cancer Res Clin Oncol; 1987; 113(3):273-8. PubMed ID: 3584216
[TBL] [Abstract][Full Text] [Related]
35. Recombinant interferon beta: a phase I-II trial in children with recurrent brain tumors.
Allen J; Packer R; Bleyer A; Zeltzer P; Prados M; Nirenberg A
J Clin Oncol; 1991 May; 9(5):783-8. PubMed ID: 2016620
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma.
Joffe JK; Perren TJ; Bradley C; Primrose J; Hallam S; Ward U; Illingworth JM; Selby PJ
Br J Cancer; 1997; 75(3):423-6. PubMed ID: 9020490
[TBL] [Abstract][Full Text] [Related]
37. A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanoma.
Creagan ET; Loprinzi CL; Ahmann DL; Schaid DJ
Cancer; 1988 Dec; 62(12):2472-4. PubMed ID: 3142675
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia.
Foon KA; Bottino GC; Abrams PG; Fer MF; Longo DL; Schoenberger CS; Oldham RK
Am J Med; 1985 Feb; 78(2):216-20. PubMed ID: 3970047
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma.
Creagan ET; Ahmann DL; Green SJ; Long HJ; Rubin J; Schutt AJ; Dziewanowski ZE
Cancer; 1984 Dec; 54(12):2844-9. PubMed ID: 6498762
[TBL] [Abstract][Full Text] [Related]
40. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
